February 25, 2019 / 6:17 AM / a month ago

Roche to buy gene therapy specialist Spark in $4.3 bln deal

ZURICH, Feb 25 (Reuters) - Roche on Monday said it will buy Spark Therapeutics in a transaction valued at $4.3 billion as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis.

Roche will acquire U.S.-based Spark for $114.50 per share, a premium of about 122 percent to Spark's closing price on Feb. 22, the Swiss company said in a statement.

Reporting by John Miller; editing by Thomas Seythal

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below